Antibody-drug conjugates for multiple myeloma

Area of Science:

• Oncology
• Pharmacology
• Immunotherapy

Background:

• Multiple myeloma (MM) is a hematologic malignancy.
• Antibody-drug conjugates (ADCs) represent a novel therapeutic class for MM.
• ADCs deliver cytotoxic agents directly to myeloma cells, minimizing off-target toxicity.

Purpose of the Study:

• To review the rationale and clinical data for ADCs in MM treatment.
• To contextualize ADCs within the evolving MM treatment landscape.
• To discuss novel agents and immunotherapies in MM development.

Main Methods:

• Review of pre-clinical and clinical data for ADCs in MM.
• Analysis of the current MM treatment paradigm.
• Inclusion of emerging immunotherapies and novel agents.

Main Results:

• ADCs demonstrate significant potential for treating MM.
• Belantamab mafodotin shows clinical responses in heavily pre-treated MM.
• ADCs can be combined with standard therapies and used in earlier treatment lines.

Conclusions:

• ADCs are a valuable addition to the MM therapeutic arsenal.
• Belantamab mafodotin is a leading ADC with demonstrated efficacy.
• Optimal management of specific ADC adverse events may require specialist input.